Active Biotech AB (publ) (STO:ACTI)

Market Cap	171.34M -11.1%
Revenue (ttm)	n/a
Net Income	-37.32M
EPS	-3.00
Shares Out	26.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,780
Open	6.36
Previous Close	6.42
Day's Range	6.20 - 6.70
52-Week Range	3.70 - 26.25
Beta	1.35
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACTI